Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma

Figure 2

Comparison of PFS and OS between different groups of HCC patients. (a) PFS between CTC-positive and CTC-negative groups; (b) OS between CTC-positive and CTC-negative groups; (c) PFS between RFA and non-RFA groups in CTC-positive HCC patients; (d) PFS between RFA and non-RFA groups in CTC- negative HCC patients; (e) OS between RFA and non-RFA groups in CTC-positive HCC patients; (f) OS between RFA and non-RFA groups in CTC-negative HCC patients. (g) PFS between RFA and nontreatment groups in CTC-positive HCC patients; (h) OS between RFA and nontreatment groups in CTC-positive HCC patients.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)